Dendritic cell immunotherapy for glioblastoma

Expert Review of Anticancer Therapy

Volumn 14, Issue 7, 2014, Pages 761-763

  Polyzoidis, Stavros ^a   Ashkan, Keyoumars ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Dendritic cell; Glioblastoma multiforme; Immunotherapy; Overall survival; Side effect

Indexed keywords

DENDRITIC CELL VACCINE; TUMOR ANTIGEN; CANCER VACCINE; TUMOR MARKER;

ALLERGIC ENCEPHALOMYELITIS; BLOOD BRAIN BARRIER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INJECTION SITE REDNESS; MELANOMA; MULTIMODALITY CANCER THERAPY; NEUROTOXICITY; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; REVIEW; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; ADVERSE EFFECTS; BRAIN NEOPLASMS; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; MORTALITY; PROCEDURES; RADIOTHERAPY;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CANCER VACCINES; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; DENDRITIC CELLS; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY; RADIOTHERAPY;

EID: 84903146610     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.2014.921571     Document Type: Review

References (31)

1. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-66
2. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12:265-77
3. Plosker GL. Sipuleucel-T: In metastatic castration-resistant prostate cancer. Drugs 2011;71(1):101-8
4. Ransohoff RM, Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat Rev Immunol 2012;12:623-35
5. Ochs K, Sahm F, Opitz CA, et al. Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma. J Neuroimmunol 2013;265:106-16
6. Motz GT, Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013;39:61-73
7. Bregy A, Wong TM, Shah AH, et al. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme. Cancer Treat Rev 2013;39:891-907
8. Ardon H, Van Gool SW, Verschuere T,et al. Integration of autologous dendritic cell-based immunotherapyin the standard of care treatment for patients with newly diagnosed glioblastoma: Results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 2012;61:2033-44
9. Phillips HS, Kharbanda S, Chen R, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73 (Pubitemid 43357943
10. Shirahata M, Iwao-Koizumi K, Saito S,et al. Gene expression-based molecular diagnostic system for malignant gliomas is superior to histological diagnosis. Clin Cancer Res 2007;13:7341-56
11. Prins RM, Soto H, Konkankit V, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011;17:1603-15
12. Rutkowski S, De Vleeschouwer S,Kaempgen E, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004;91: 1656-62 (Pubitemid 39546137
13. De Vleeschouwer S, Fieuws S, Rutkowski S,et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008;14:3098-104
14. The Cancer Genome Atlas Research Network. Comprehensive genomic characterization Defines human glioblastoma genes and core pathways. Nature 2008; 455(7216):1061-8
15. Sturm D, Bender S, Jones DTW, et al. Paediatric and adult glioblastoma: Multiform (epi)genomic culprits emerge. Nat Rev Cancer 2014;14:92-107
16. Yamanaka R, Abe T, Yajima N, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: Results of a clinical phase I/II trial. Br J Cancer 2003;89:1172-9 (Pubitemid 37363398
17. Sampson JH, Archer GE, Mitchell DA,et al. An epidermal growth factor receptor variant III-Targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009;8: 2773-9
18. Sampson JH, Heimberger AB, Archer GE,et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 2010;28:4722-9
19. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-Associated antigen peptides and clinical activity by vaccinations with {alpha}-Type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 2011;29:330-6
20. Jie X, Hua L, Jiang W, et al. Clinical application of a dendritic cell vaccine raised against heat- shocked glioblastoma. Cell Biochem Biophys 2012;62:91-9
21. Phuphanich S, Wheeler CJ, Rudnick JD,et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013;62:125-35
22. Akiyama Y, Oshita C, Kume A, et al. a-Type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: A phase I clinical trial. BMC Cancer 2012;12:623
23. Aarntzen EH, Srinivas M, De Wilt JH,et al. Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy- Thymidine ([18F]FLT) PET imaging. Proc Natl Acad Sci USA 2011;108:18396-9
24. Galluzzi L, Senovilla L, Zitvogel L,Kroemer G. The secret ally: Immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012;11:215-33
25. Wheeler CJ, Black KL, Liu G, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res 2008;68: 5955-64
26. Liau LM, Prins RM, Kiertscher SM, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005;11:5515-25 (Pubitemid 41060828
27. Heimberger AB, Sun W, Hussain SF, et al. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. Neuro Oncol 2008;10:98-103 (Pubitemid 351250906
28. Chang CN, Huang YC, Yang DM, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 2011;18:1048-54
29. Friedman EJ. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr Pharm Des 2002;8:1765-80 (Pubitemid 34846202
30. Kjaergaard J, Wang LX, Kuriyama H, et al. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-Tumor cell fusion vaccines. J Neurosurg 2005;103:156-64 (Pubitemid 43193947
31. Cancer research UK. Available from: Www.cancerresearchuk.org/cancer-help/ trials/a-Trial-of-A-vaccine-called-dcvax-l-forglioblastoma-multiforme.